Malignant Carcinoid Syndrome: all 59 studies

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine NeoplasmCompletedNCT03453489Phase 2Results posted
• Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELOCompletedNCT03223428Results posted
• Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine TumorsCompletedNCT02259725Phase 2Results posted
• Telotristat Etiprate for Carcinoid Syndrome TherapyCompletedNCT02063659Phase 3Results posted
• Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome SymptomsCompletedNCT02026063Phase 3Results posted
• P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid SyndromeTerminatedNCT01886287Phase 2Results posted
• TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)CompletedNCT01677910Phase 3Results posted
• Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid SyndromeCompletedNCT01104415Phase 2Results posted
• Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid SyndromeTerminatedNCT01018953Phase 2Results posted
• Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell CancerCompletedNCT01010126Phase 2Results posted
• Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide TherapyCompletedNCT00853047Phase 2Results posted
• An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid SyndromeCompletedNCT00774930Phase 3Results posted
• Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine TumorsTerminatedNCT00730483Not applicableResults posted
• Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine CancerCompletedNCT00454363Phase 2Results posted
• AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine TumorsCompletedNCT00427349Phase 2Results posted
• Everolimus and Octreotide in Patients With Advanced Carcinoid TumorCompletedNCT00412061Phase 3Results posted
• Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine TumorsTerminatedNCT00227617Phase 2/3Results posted
• Temsirolimus in Treating Patients With Metastatic Neuroendocrine CarcinomaCompletedNCT00093782Phase 2Results posted
• Pilot Study for Cyproheptadine in Hospitalized Patient for COVID-19Status unknownNCT04876573Phase 2
• Cyproheptadine in Severe COVID-19 : A Unblinded Randomized TrialStatus unknownNCT04820751Phase 3
• Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid SyndromeWithdrawnNCT04776876Phase 2
• Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat EthylWithdrawnNCT04713202Phase 2
• Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation OptimisationTerminatedNCT04140409Phase 4
• Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel FrequencyTerminatedNCT04073017Not applicable
• Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid SyndromeWithdrawnNCT04065165Phase 3
• Carcinoid Heart Disease and Peptide Receptor Radiotargetted TherapyStatus unknownNCT04039516Phase 2
• Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETsCompletedNCT03722511Phase 2
• Study to Evaluate the Use of Resources and the Costs Associated With Carcinoid Syndrome (CS) in Patients With NETs in SpainCompletedNCT03220087
• An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in MalesCompletedNCT01932528Phase 1
• Effects of Serotonin Excess on Bone in Carcinoid SyndromeCompletedNCT01430871
• A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of DiarrheaCompletedNCT01234168
• Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine CarcinomaCompletedNCT01204476Phase 1
• Study of Panitumumab in the Treatment of Carcinoid SyndromeWithdrawnNCT01172717Phase 2
• Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid TumorsCompletedNCT01155258Phase 1
• Azilect + Antidepressant Chart ReviewCompletedNCT00955604
• Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid SyndromeTerminatedNCT00884715Phase 1/2
• Everolimus and Vatalanib in Treating Patients With Advanced Solid TumorsCompletedNCT00655655Phase 1
• Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal CancerCompletedNCT00654160Phase 1
• Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine TumorsCompletedNCT00602082Phase 2
• Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine TumorsStatus unknownNCT00454376
• Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By SurgeryCompletedNCT00416767Phase 2
• Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerCompletedNCT00397384Phase 1
• Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine TumorsWithdrawnNCT00227773Phase 2
• Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid SyndromeTerminatedNCT00092287Phase 3
• EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung CancerTerminatedNCT00087191Not applicable
• Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine TumorsTerminatedNCT00084461Phase 2
• Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine TumorsCompletedNCT00075439Phase 2
• Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid TumorsCompletedNCT00055809Phase 2
• Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid TumorsCompletedNCT00049023Phase 1
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1
• Thalidomide in Treating Patients With Metastatic Neuroendocrine TumorsCompletedNCT00027638Phase 2
• Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract CancerCompletedNCT00019474Phase 2
• PS-341 in Treating Patients With Metastatic Neuroendocrine TumorsCompletedNCT00017199Phase 2
• Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent CancerCompletedNCT00006368Phase 1
• Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal ObstructionCompletedNCT00004910Phase 1/2
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
• Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal CancerCompletedNCT00003427Phase 1
• Indium In 111 Pentetreotide in Treating Patients With Refractory CancerTerminatedNCT00002947Phase 1
• Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid TumorsCompletedNCT00002470Phase 2

← Malignant Carcinoid Syndrome overview